AUA
  • Program
  • Register
  • Meeting Coverage
  • Guidelines
  • Industry Highlights
  • Science & Technology Hall
  • Photo Gallery
Topics
  • Meeting Coverage
  • Guidelines
  • Industry Highlights
  • Science & Technology Hall
  • Photo Gallery
Resources
  • Program
  • Register
Twitter X icon Facebook iconInstagram iconYouTube iconLinkedIn icon
May 21, 2021

Overactive bladder symptom relief is goal of pharmacotherapy

Explore the various pharmacotherapies for OAB while reviewing the principles of physiology and pharmacotherapy for currently available agents.


Large Wein
Alan J. Wein, MD, PhD (hon), FACS

Aua Events PharmacoSuccessfully managing patient expectations with the effective use of pharmacotherapy has brought new hope to people diagnosed with overactive bladder (OAB).

The focus of Friday’s session, “Contemporary Pharmacotherapy for OAB 2021: Monotherapy and Combined Pharmacotherapy to Optimize Treatment,” is the challenge of bringing symptom relief to this bothersome condition. Although there is not a cure for OAB, one of the session’s presenters, Alan J. Wein, MD, PhD (hon), FACS, said clinicians and patients can work together to improve quality of life. Dr. Wein is a professor and emeritus chief of urology at the Perelman School of Medicine at the University of Pennsylvania in Philadelphia, as well as director of its residency program in urology. 

“It is important to set proper patient expectations regarding treatment of OAB and the potential need for sequential and even additive therapies,” Dr. Wein said. “The quickest way to get a dissatisfied patient is to promise something you cannot deliver.”

Much of the session will focus on defining the similarities and differences between the various oral pharmacotherapies for OAB while reviewing the principles of physiology and pharmacotherapy for currently available agents. According to Dr. Wein, the discussion will explore oral therapy only: antimuscarinics, beta-3 agonists, alpha-adrenergic antagonists, phosphodiesterase inhibitors and combinations. It also will include information on drugs in development and new therapy concepts. The discussion will include only peripheral details about third line treatments.

There are clinical (and theoretical) advantages and limitations for each class of OAB drug therapy. Antimuscarinics inhibit the sensation of bladder filling, whereas beta-3 agonists create a relaxing effect on the detrusor smooth muscle. However, literature suggests that antimuscarinics have been linked to cognitive impairment in elderly patients. Additionally, there are concerns regarding some beta-3 agonists related to hypertension and cardiac issues, Dr. Wein said.

“Guidelines suggest that there are no meaningful differences between antimuscarinics with respect to efficacy,” Dr. Wein said. “Both antimuscarinics and beta-3 agonists block urgency, which is defined as the abrupt need to urinate. Antimuscarinics in the usual doses do not affect voluntary urination. The same can be said about beta-3 agonists.”

According to Dr. Wein, each drug class has a different mechanism of action (MOA). Therefore, it is possible to combine two class types for treatment. In fact, he said, urologists often achieve better results combining two different types of treatments than by just increasing the dose of one.

There are some issues related to patient compliance, he said. The discontinuation rate is higher for antimuscarinics, as patients do not like the balance between efficacy and side effects. Thus, discussing patient expectations is critical.

“We focus on telling the patients that the goal is not a cure, but rather a significant improvement of symptoms,” he said. “We have to tell patients to be realistic, too. There are things they can do in combination with drug therapy to treat the bothersome symptoms of OAB.”

As such, Dr. Wein will discuss the importance of therapeutic algorithms in improving patient outcomes. These include such factors as an accurate OAB diagnosis, behavioral modification (fluid intake, prophylactic voiding, planned trips to the bathroom, keeping a voiding diary, etc.) and learning to how to suppress the sensation of urgency.

“Guidelines say to start behavioral modification therapies first and then add drug treatment if this is not successful. Personally, I start them both at the same time,” Dr. Wein said. “Studies show the combined approach is more effective than either one separately.”

Visit AUA2021 Daily News Online for more articles.

Interesting Stories
YONSA® (abiraterone acetate) Holds a Full House of Benefits—See Booth 1222
Sponsored by Sun Pharma
YONSA® (abiraterone acetate) Holds a Full House of Benefits—See Booth 1222
Register for the Career Fair at AUA2025
Sponsored by AUA
Register for the Career Fair at AUA2025
Book your AUA2025 housing now
Sponsored by AUA
Book your AUA2025 housing now
More Content
Getty Images 1208851295
AUA2022
Save the date
Jan 31, 2022
Aua Wrap 04
AUA2021
AUA2021 On Demand: see what’s streaming
Sep 22, 2021
Aua Wrap 03
AUA2021
Satellite symposia bring expert insights
Sep 22, 2021
Aua Wrap 01
AUA2021
Education and training for young urologists
Sep 22, 2021
Getty Images 1199215126
AUA2021
Claim your CME
Sep 22, 2021
Aua Wrap 05
AUA2021
Read all about it
Sep 22, 2021
Aua Tv
AUA2021
Must-see TV
Sep 22, 2021
Getty Images 185224486
AUA2021
AUA2021: By the numbers
Sep 15, 2021
Toni K. Choueiri, MD
AUA2021
Late-breaking science
Sep 15, 2021
Ian M. Thompson Jr., MD
AUA2021
Award winners
Sep 15, 2021
Tips And Tricks
AUA2021
Guideline updates
Sep 15, 2021
Ai
AUA2021
New technology
Sep 15, 2021
AUA
Twitter X icon Facebook iconInstagram iconYouTube iconLinkedIn icon
© 2025 Ascend Media. All rights reserved.